Skip to main content
. 2000 Oct 10;97(21):11466–11471. doi: 10.1073/pnas.97.21.11466

Figure 2.

Figure 2

Tat antagonizes signaling by CXCR4, but not CCR5, agonists. (Panel 1) Tat wild-type (wt) (residues 11–50), but not Tat-mCXC (cysteines at residues 25 and 27 changed to alanines), peptide-desensitized SDF-1-induced calcium mobilization. Tat peptides were added 50–100 s before SDF-1; measurements of calcium flux followed. Tat wt peptide did not affect RANTES signaling in PBMCs (panel 2) and monocytes (panel 3); nor MIP1α (panel 4) or MIP1β (panel 5) signaling in PBMCs. In each panel, the top tracing is the addition of chemokine alone (100 nM) whereas the bottom tracing(s) is pretreatment with Tat peptide(s) (200 nM), followed by addition of indicated chemokine (100 nM).